Comparison · NCT03829969-e10a34cc
Toripalimab vs Placebo: PFS
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Toripalimab vs Placebo: PFS. Trial comparisons, record NCT03829969-e10a34cc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03829969-e10a34cc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.498 | 0.437 | 0.559 | wilson | |
| Risk in group 2 | 0.65 | 0.59 | 0.706 | wilson | |
| Risk difference, group 1 minus group 2 | -0.152 | -0.234 | -0.0663 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.766 | 0.658 | 0.892 | log | |
| Odds ratio, group 1 over group 2 | 0.535 | 0.375 | 0.762 | log | |
| Number needed to treat, for one fewer participant with the outcome on Toripalimab than on Placebo | 6.59 | 4.27 | 15.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Toripalimab | Toripalimab combine with paclitaxel and cisplatin~Toripalimab: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy | 128 | 257 | OG000 |
| Group 2 | Placebo | Placebo combine with paclitaxel and cisplatin~Toripalimab: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy | 167 | 257 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- PFS
- Description
- To evaluate the efficacy of JS001 plus chemotherapy compared with placebo plus chemotherapy，as measured by investigator-assessed progression free survival (PFS) according to RECIST v1.1
- Time frame
- Up to 2 approximately years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
- NCT number
- NCT03829969
- Phases
- PHASE3
- Conditions
- Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
- Interventions
- Toripalimab
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Results first posted
- 2024-05-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03829969?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03829969-e10a34cc